Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Consolidated Net Income/Loss of $-3.20M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-3.20M |
|
-- |
|
-- |
|
$3.27M |
|
$-3.27M |
|
$0.08M |
|
$-3.19M |
|
$-3.19M |
|
$-3.20M |
|
$-3.20M |
|
|
Consolidated Net Income/Loss |
$-3.20M |
$-3.20M |
|
$-3.27M |
|
$-3.27M |
|
7.02M |
|
7.02M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$23.56M |
|
-- |
|
-- |
|
$23.56M |
|
$6.12M |
|
-- |
|
-- |
|
$6.12M |
|
$17.44M |
|
$17.44M |
|
$17.44M |
|
12.81M |
|
| Cash Flow Statement Financials | |
$-3.80M |
|
-- |
|
$11.55M |
|
$14.44M |
|
$22.19M |
|
$7.75M |
|
$0.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.85 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.33% |
|
-18.33% |
|
-13.57% |
|
-18.33% |
|
$1.36 |
|
$-0.54 |
|
$-0.54 |
|